test

Ruth Halaban PhD

Senior Research Scientist in Dermatology

Research Interests

Genes controlling differentiation, proliferation; malignant transformation of melanocytes; Growth factors and receptor kinases; Signal transduction; Epigenetic modification and gene expression; Markers for melanoma; Next-Generation sequencing; mutations


Research Summary

Genes controlling differentiation, proliferation and malignant transformation of melanocytes, growth factors and receptor kinases, signal transduction, epigenetic modification and gene expression, markers for melanoma


Selected Publications

  • Shi, H., G. Moriceau, X. Kong, R.C. Koya, R. Nazarian, G.M. Pupo, A. Bacchiocchi, K.B. Dahlman, B. Chmielowski, J.A. Sosman, R. Halaban, R.F. Kefford, G.V. Long, A. Ribas, and R.S. Lo. 2012. Preexisting MEK1 Exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov. 2:414-424.
  • Davis, M.J., B.H. Ha, E.C. Holman, R. Halaban, J. Schlessinger, and T.J. Boggon. 2013. RAC1P29S is a spontaneously activating cancer-associated GTPase. Proc Natl Acad Sci U S A. 110:912-917.
  • Ha, B.H., M.J. Davis, C. Chen, H.J. Lou, J. Gao, R. Zhang, M. Krauthammer, R. Halaban, J. Schlessinger, B.E. Turk, and T.J. Boggon. 2012. Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate. Proc Natl Acad Sci U S A.
  • Krauthammer, M., Y. Kong, B.H. Ha, P. Evans, A. Bacchiocchi, J.P. McCusker, E. Cheng, M.J. Davis, G. Goh, M. Choi, S. Ariyan, D. Narayan, K. Dutton-Regester, A. Capatana, E.C. Holman, M. Bosenberg, M. Sznol, H.M. Kluger, D.E. Brash, D.F. Stern, M.A. Materin, R.S. Lo, S. Mane, S. Ma, K.K. Kidd, N.K. Hayward, R.P. Lifton, J. Schlessinger, T.J. Boggon, and R. Halaban. 2012. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet. 44:1006-1014
  • Halaban, R., W. Zhang, A. Bacchiocchi, E. Cheng, F. Parisi, S. Ariyan, M. Krauthammer, J.P. McCusker, Y. Kluger, and M. Sznol. 2010. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF(WT) melanoma cells. Pigment Cell Melanoma Res. 23:190-200.
  • Koga, Y., Pelizzola, M., Cheng, E., Krauthammer, M., Sznol, M., Ariyan, S., Narayan, D., Molinaro, A. M., Halaban, R., and Weissman, S. M. Genome-wide screen of promoter methylation identifies novel markers in melanoma. Genome Res, published online June 2, 2009.
  • Halaban, R., Krauthammer, M. Pelizzola, M., Cheng, E., Kovacs, D. Sznol, M. Ariyan, S. Narayan, D., Bacchiocchi, A., Molinaro, A., Kluger, K. Deng, M., Tran, N. Zhang, W. Picardo, M., Enghild, JJ. (2009), Integrative Analysis of Epigenetic Modulation in Melanoma Cell Response to Decitabine: Clinical Implications. PlosOne, 4, e4563
  • Pelizzola, M., Y. Koga, et al. (2008). MEDME: An experimental and analytical methodology for the estimation of DNA methylation levels based on microarray derived MeDIP-enrichment. Genome Res 18: 1652-9.

Edit Profile